Related Experiment Video
Updated: Mar 16, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
Coronary sinus-based percutaneous annuloplasty as treatment for functional mitral regurgitation: the TITAN II trial
Janusz Lipiecki1, Tomasz Siminiak2, Horst Sievert3
1Centre de Cardiologie Interventionnelle, Pôle Santé République Clermont-Ferrand , France.
Insights
A modified Carillon device effectively treats functional mitral regurgitation (FMR) in heart failure patients. This percutaneous therapy improved patient outcomes and resolved previous device fracture issues, paving the way for further trials.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Research
Background:
- Functional mitral regurgitation (FMR) worsens outcomes in congestive heart failure (CHF) and cardiomyopathy patients.
- Percutaneous coronary sinus-based therapies aim to reduce FMR.
Purpose of the Study:
- Evaluate the safety and efficacy of a modified Carillon device for FMR treatment.
- Assess the modified device's performance in patients with cardiomyopathy and FMR.
Main Methods:
- 36 patients with CHF, reduced ejection fraction (<40%), and moderate-to-severe FMR received the Carillon device implant.
- The study monitored adverse events, FMR severity, functional class, and 6-minute walk tests.
Main Results:
- One non-device-related death occurred within 30 days post-implant.
- Significant reductions in FMR and improvements in functional class and walk tests were observed.
- Crucially, the issue of device anchor fractures seen in prior studies was not observed.
Conclusions:
- The modified Carillon device shows promise for treating FMR, improving clinical and echocardiographic parameters.
- This revised device successfully addressed the prior anchor fracture problem.
- The modified device is slated for use in an upcoming blinded, randomized trial for symptomatic FMR patients.
Objective:
Functional (or secondary) mitral regurgitation (FMR) is associated with greater morbidity and worse outcomes in patients with congestive heart failure (CHF) and cardiomyopathy. The Carillon® Mitral Contour System® is a coronary sinus-based percutaneous therapy to reduce FMR. We evaluated the safety and efficacy of a modified version of the Carillon device in the treatment of patients with cardiomyopathy and FMR.
Methods:
36 patients with CHF, depressed left ventricular function (ejection fraction <40%) and at least moderate FMR underwent the Carillon device implant.
Results:
There was 1 major adverse event within 30 days-a death (not device related)-occurring 17 days after the implant. Reductions in FMR and improvements in functional class and 6 min walk tests were seen, similar to prior studies. Device fractures in the high strain region of the proximal anchor (seen in prior studies) were not seen in this study.
Conclusions:
The modified Carillon device was associated with improvements in clinical and echocardiographic parameters in treating patients with FMR, while successfully addressing the issue of anchor fracture. This version of the Carillon device will be used in a blinded randomised trial of symptomatic patients with FMR.
Related Concept Videos
Mitral Stenosis III: Medical Management
Mitral Regurgitation III: Medical Management
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Regurgitation II: Clinical Features and Diagnostic Tests
Mitral Valve Prolapse II: Assessment and Management
Mitral Regurgitation IV: Nursing Management

